Quick Answer
Vivos Therapeutics, Inc. reported Stockholders Equity of $7.95 million for the year ending 2024.
- Vivos Therapeutics, Inc. showed an increase of +1,835.3% in Stockholders Equity from 2023 to 2024.
- This data is from Vivos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.51 million | Q2 2020: -$2.20 million | Q3 2020: -$1.93 million | Q1 2021: $14.34 million | Q2 2021: $36.48 million | Q3 2021: $32.47 million | Q1 2022: $21.04 million | Q2 2022: $14.84 million | Q3 2022: $9.86 million | Q1 2023: $6.99 million | Q2 2023: $2.11 million | Q3 2023: $46.0 thousand | Q4 2023: $411.0 thousand | Q1 2024: $582.0 thousand | Q2 2024: $6.35 million | Q3 2024: $7.67 million | Q4 2024: $7.95 million | Q1 2025: $4.41 million | Q2 2025: $4.58 million | Q3 2025: $2.53 million.
- Over the full 7 years of available data (2018 to 2024), Vivos Therapeutics, Inc.'s Stockholders Equity has grown by 64.8%.
- Historical annual values: Fiscal year 2024: $7.95 million | Fiscal year 2023: $411.0 thousand | Fiscal year 2022: $4.80 million | Fiscal year 2021: $25.54 million | Fiscal year 2020: $16.92 million | Fiscal year 2019: -$2.94 million | Fiscal year 2018: $4.83 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: